Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

CLEC5A

  • Michael E. Reschen
  • Christopher A. O’Callaghan
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_572

Synonyms

Historical Background

CLEC5A is a type 2 transmembrane receptor originally identified by its ability to stabilize DAP (DNAX associating protein)-12 at the cell surface in myeloid cells (Bakker et al. 1999). It is emerging as a key component of the innate immune system; it activates macrophages, regulates osteoclastogenesis, and plays a role in inflammatory diseases including dengue virus-induced lethality, Japanese encephalitis-associated neuro-inflammation, and autoimmune arthritis (Bakker et al. 1999; Chen et al. 2008; Aoki et al. 2009; Joyce-Shaikh et al. 2010; Chen et al. 2012).

Structure

The predicted 161 amino acid extracellular sequence of CLEC5A contains a C-type lectin-like domain in the carboxy-terminal region (UniProt 2015). The N-terminal cytoplasmic tail is predicted to be only four amino acids in length and, thus, lacks a signaling motif (UniProt 2015). The putative 23 amino acid single pass transmembrane domain contains a conserved lysine residue. CLEC5A associates with DAP-12 by an interaction between this positively charged lysine and a negatively charged aspartate residue that is present in the transmembrane region of DAP-12 (Bakker et al. 1999). DAP-12 transduces activating signals in myeloid and natural killer cells and contains an immunoreceptor tyrosine activation motif (ITAM) in its cytosolic domain (Lanier 2009). Ligand binding by DAP-12-associated receptors in myeloid cells results in phosphorylation of the two key tyrosine residues within the ITAM motif by  Src kinases. The two SH2 domains of Syk (Spleen tyrosine kinase) then bind to the phosphorylated ITAM, resulting in Syk activation (Aoki et al. 2003; Lanier 2009). DAP-12 has a very short extracellular domain and exists as a disulfide linked homodimer in association with CLEC5A or another member of the set of receptors with which it interacts (Lanier et al. 1998; Bakker et al. 1999).

In mouse osteoclasts and bone marrow-derived macrophages, CLEC5A has been shown to associate with both the 10 kDa transmembrane protein, DAP-10 as well as DAP-12 to form a trimolecular complex (Inui et al. 2009). DAP-10 has a cytosolic signaling motif defined by the sequence YINM that when phosphorylated recruits phosphatidylinositol-3 kinase ( PI3K) and growth factor receptor-bound protein 2 (Grb2). Grb2 then interacts with the Proto-oncogene vav (Vav1), a guanine nucleotide exchange factor (Tybulewicz 2005; Upshaw et al. 2006; Lanier 2008). Thus, CLEC5A can access two distinct pathways (see Fig. 1 for a schematic representation of these signaling pathways).
CLEC5A, Fig. 1

Signaling mechanism of CLEC5A. The positively charged lysine residue (K) in CLEC5A’s transmembrane domain interacts with a negatively charged aspartate residue (D) in the DAP-12 or DAP-10 transmembrane domain. Activation of CLEC5A results in phosphorylation of DAP-12 and/or DAP-10 which allows signaling through distinct pathways. DAP12 forms a disulfide-bonded homodimer which contains an ITAM in its intracellular domain. Upon phosphorylation, Syk kinases are activated which trigger a signaling cascade that leads to intracellular calcium release and production of chemokines and cytokines. In osteoclasts, DAP-10 can form a heterodimer with DAP-12 and signal through a distinct pathway, ultimately causing osteoclastogenesis and bone remodeling. The intracellular domain of DAP-10 contains a YINM motif which when phosphorylated recruits the p85 subunit of Pi(3)K and a complex of Grb2-Vav1-SOS. CLEC5A interacts directly with the Dengue and Japanese encephalitis viruses, but specific exogenous or endogenous ligands have not yet been identified

The structure of the extracellular domain of human CLEC5A has been solved using X-ray crystallography to a resolution of 1.9 Å (Watson and O’Callaghan 2010; Watson et al. 2011). Although the overall formation was consistent with a C-type lectin-like molecule, several features were unique and suggested a mechanism for ligand binding. The long loop region of crystallized CLEC5A exhibited two conformations (Watson et al. 2011). In one conformation, an extra beta-strand was formed that would reduce loop flexibility and increase stability of the protein core (Watson et al. 2011). It was hypothesized that ligand binding (or stabilization by the crystal lattice) could cause this altered conformation, that is, in effect, a molecular switch. Computational analysis suggested this switch could enhance DAP12 binding and signal transduction (Watson et al. 2011). Similar to other C-type lectins, three disulfide bonds and noncovalent interactions maintained the core of CLEC5A. Using BRET CLEC5A was found to form nonconstitutive homodimers at the cell surface in transfected cells (Watson et al. 2011).

Orthologs of the CLEC5A gene have been identified in several species, including rat, mouse, dog, pig, cow, and chimpanzee (Bakker et al. 1999; Yim et al. 2001). In vitro studies have shown murine and porcine CLEC5A to be glycosylated (Yim et al. 2001; Aoki et al. 2009). Glycosylation is greater in murine neutrophils than macrophages, and these differences may influence ligand binding (Aoki et al. 2009).

A precise endogenous or exogenous ligand for CLEC5A has not been found, but human and mouse CLEC5A react directly with dengue virus (DV) strain 2 in a calcium-independent manner (Chen et al. 2008). This interaction can be inhibited in vitro by the monosaccharide fucose, suggesting that DV envelope protein glycans are important in mediating this interaction (Chen et al. 2008). Human CLEC5A also reacts with DV serotypes 1, 3, and 4 (Watson et al. 2011). Screening of a glycolipid array and oligosaccharide array, each with over 400 compounds, did not reveal significant binding (Watson et al. 2011). Both human and mouse CLEC5A bind to Japanese Encephalitis virus (by ELISA) and binding is absent from a splice variant lacking 23 amino acids from the stalk region (25aa in the mouse splice variant) (Chen et al. 2012).

Function

Macrophages are phagocytic cells derived from monocytes and play a key role in immunity. CLEC5A has a role in macrophage activation (Bakker et al. 1999). When the mouse macrophage cell line J774 is transfected with CLEC5A, cross-linking of CLEC5A/DAP-12 complexes results in calcium mobilization (Bakker et al. 1999). Signaling through CLEC5A in murine myeloid 32Dcl3 cells upregulates expression of the leukocyte adhesion molecule CD11b and of cytokines, including RANTES (regulated upon activation normal T-cell expressed and presumably secreted), IP-10 (Interferon-gamma-induced protein 10), and MDC (macrophage-derived chemokine) (Aoki et al. 2009). Stimulation of  Toll-like receptor 4 by lipopolysaccharide had a synergistic effect with CLEC5A on the expression of RANTES and MDC (Aoki et al. 2009). IL-23 stimulation increases CLEC5A binding to DAP12 and DAP10 in human PBMC (peripheral blood mononuclear cells) as measured by immunoprecipitation (Shin et al. 2015). CLEC5A interacts with DV causing DAP-12 phosphorylation, triggering tumor necrosis factor (TNF)-α production (Chen et al. 2008). Conversely, knockdown of CLEC5A suppresses the release of TNF-α, IL-6, IL-8, macrophage inflammatory protein (MIP), and IP-10 in response to DV (Chen et al. 2008). Signaling through CLEC5A in GM-CSF differentiated macrophages contributes to NLRP3 inflammasome activation and secretion of IL-1β and IL-18 (Wu et al. 2013). In a mouse model of lethal shock, CLEC5A activation on myeloid cells causes nitric oxide release, contributing to disease severity (Cheung et al. 2011). Overall, signaling through CLEC5A in myeloid cells triggers the release of inflammatory mediators contributing to inflammation.

CLEC5A also has a role in bone metabolism. Bone homeostasis depends on the opposing action of osteoblasts of mesenchymal origin that promote bone-matrix formation and osteoclasts derived from myeloid precursor cells that enhance bone resorption. Stimulation of CLEC5A enhances osteoclastogenesis from murine bone marrow-derived monocytes by signaling through DAP-10 and DAP-12 (Inui et al. 2009; Joyce-Shaikh et al. 2010). DV infection of monocyte-derived osteoclasts triggers TNF-α and IL-6 release that is abrogated by a CLEC5A blocking antibody (Huang et al. 2016). CLEC5A knockout mice showed less osteolytic activity in response to DV infection (Huang et al. 2016).

Expression

General Expression Pattern

In humans, CLEC5A is expressed in peripheral blood monocytes and in the monocyte/macrophage cell lines U937 and MonoMac6 but not in cells of non-myeloid origin (Bakker et al. 1999). Surface expression of CLEC5A was detected on human peripheral blood cells expressing either CD66 or CD14+ (Chen et al. 2008). In another study CLEC5A expression by flow cytometry with gating for both CLEC5A and DAP12 in PBMCs was found to be mainly confined to CD16+ cells rather than CD14+ cells (Shin et al. 2015). CLEC5A is expressed on porcine monocytes and pulmonary alveolar macrophages but not lymphocytes or polymorphonuclear granulocytes (Yim et al. 2001). In mice, CLEC5A expression has been detected on granulocytes (CD11b+ Ly6Ghigh) and monocytes (CD11b+ Ly6Glow) from bone marrow and peripheral blood, on peritoneal macrophages, thioglycollate-elicited neutrophils, and osteoclasts (Aoki et al. 2009; Inui et al. 2009; Joyce-Shaikh et al. 2010). In humans and mice, the main tissue sites of expression are in bone marrow, synovium/joint, and lung (Joyce-Shaikh et al. 2010). In inflamed pannus from patients with rheumatoid arthritis, CLEC5A was expressed in CD68+ macrophages (Joyce-Shaikh et al. 2010).

Response to Differentiation

CLEC5A expression is affected by cell ontogeny. CLEC5A expression is higher in peripheral blood-derived CD14+ mature monocytes than in undifferentiated CD34+ bone marrow cells (Gingras et al. 2002). Expression is lower in fetal tissue compared to adult tissue and in malignant cells compared to normal cells (Gingras et al. 2002). Differentiation of myeloid precursor 32Dcl3 cells into neutrophils induces CLEC5A expression (Aoki et al. 2009). CLEC5A induction during differentiation of myeloid precursor cell line HL60 was in part dependent on expression of the myeloid master transcription factor PU.1 (Batliner et al. 2011). PU.1 binds to the promoter of CLEC5A in U937 cells inducing a transcriptional response (Batliner et al. 2011). Human monocyte-derived osteoclasts express surface levels of CLEC5A similar to that of macrophages (Huang et al. 2016). CLEC5A mRNA and protein levels were upregulated on peripheral blood mononuclear cells after 8 days of treatment with RANKL or IL-23 compared to M-CSF alone (Shin et al. 2015). CLEC5A cell surface and mRNA expression was higher in GM-CSF-derived compared to M-CSF-derived human (Wu et al. 2013; Gonzalez-Dominguez et al. 2015). However, others have reported a reduction in mRNA CLEC5A expression when monocytes are differentiated into a dendritic phenotype by stimulation with GM-CSF and IL-4 (Bakker et al. 1999).

Response to Inflammatory Stimuli

CLEC5A expression on monocytes is increased by IL-1β, TNF-α, and TGF-1β and suppressed by IL-10 (Gonzalez-Dominguez et al. 2015). Surface expression of murine CLEC5A is upregulated during pulmonary mycobacterial infection and correlates with upregulation of the type 1 cytokines TNF-α and IFN-γ (Aoki et al. 2004). However, whereas TNF-α is critical for induction of CLEC5A during murine pulmonary mycobacterial infection, IFN-γ suppressed CLEC5A expression (Aoki et al. 2004). Cigarette smoke increases surface expression of CLEC5A in alveolar macrophages from mice and humans (Wortham et al. 2016). In inflammatory bowel disease, there is an increased number of CLEC5A expressing macrophages in diseased compared with healthy intestine (Gonzalez-Dominguez et al. 2015). CLEC5A has been suggested as a marker of inflammatory tissue macrophages (Gonzalez-Dominguez et al. 2015).

Genetics and Splice Variants

The human CLEC5A gene is on chromosome 7 and encodes a 3524 base pair mRNA (NM_013252.2) (Maglott et al. 2007). The mRNA includes a 567 nucleotide open reading frame that codes for a 188 amino acid protein (Uniprot identifier: Q9NY25–1). The mouse CLEC5A gene is located on chromosome 6 and the 573 nucleotide open reading frame encodes a 190 amino acid protein (Uniprot identifier: Q9R007). Data from large-scale sequencing projects indicates the presence of multiple single nucleotide polymorphisms in the coding sequence of CLEC5A, but the majority of these have not been subjected to further experimentation (Genomes Project et al. 2012).

CLEC5A exists as alternatively spliced variants in mice and pigs, with the noncanonical isoforms lacking 25 and 19 amino acids in their extracellular domains, respectively (Bakker et al. 1999; Yim et al. 2001). The significance of these alternatively spliced transcripts is unknown.

CLEC5A−/− mice display a dysregulated bone phenotype with irregular trabecular bone connectivity (Joyce-Shaikh et al. 2010). DAP-10−/− mice display mild osteopetrosis and a reduction in the number of osteoclasts (Inui et al. 2009). DAP-12-deficient mice also display altered T-cell activity due to impaired antigen priming (Bakker et al. 2000). They have impaired osteoclast development and function and macrophages that are hyperresponsive to in vitro exposure to TLR ligands (Lanier 2008, 2009). In humans, lack of DAP-12 results in Nasu-Hakola disease, characterized by presenile dementia and bone cysts (Aoki et al. 2003). However, it is important to note that DAP-12 interacts with a multitude of cell membrane receptors, so this effect is not necessarily mediated by CLEC5A.

A case-control study examining the effect of 4 SNPs in CLEC5A exons or the 5’UTR found no association between markers of Kawasaki disease and response to treatment in a Taiwanese population (Yang et al. 2012). The rs1285933 SNP is associated with both expression level of CLEC5A in monocytes (expression quantitative trait locus) and shows borderline significance for association with severity of DV infection in a Brazilian pediatric population (TT genotype increased severity) (Zeller et al. 2010; Xavier-Carvalho et al. 2013).

Function in Disease

A role for CLEC5A is evident in the immune response and pathogenesis of several infections and in inflammatory arthritis. Infection of macrophages with DV that contains a ligand for CLEC5A caused phosphorylation of DAP-12, but knockdown of CLEC5A did not reduce viral replication, suggesting that the interaction is important in the inflammatory changes associated with the disease rather than the mechanisms of cellular infection (Chen et al. 2008). In vivo blockade of the DV-CLEC5A interaction with an antagonistic anti-CLEC5A antibody reduced lethality of DV infection in STAT−/− mice with decreased plasma leakage and hemorrhage, but did not suppress viral replication (Chen et al. 2008). CLEC5A also binds to another flavivirus, Japanese encephalitis virus (Chen et al. 2012). Mouse infection was associated with increased expression of CLEC5A in brain and splenic tissue and was associated with increased IFN-γ, TNF-α, and IL-1α production (Gupta et al. 2010). Administration of a CLEC5A blocking antibody did not prevent neuronal infection but reduced neuro-inflammation and lethality (Chen et al. 2012). Mouse pulmonary mycobacterial infection induced CLEC5A expression, suggesting a role in mycobacterial immunity (Aoki et al. 2004).

CLEC5A has recently been shown to have an important role in autoimmune-mediated synovial injury and bone erosion. In a mouse model of inflammatory arthritis models, CLEC5A stimulation increased mRNA expression of pro-inflammatory cytokines (IL-1β, IL-6, IL-17, TNF-α), bone remodeling genes (receptor activator of NF-κB ligand, Tartrate-resistant acid phosphatase, matrix metallopeptidase 9, ATPV0D2), and myeloid associated genes (CXCL1, CD11b, DAP-12, RANK) (Joyce-Shaikh et al. 2010). Activation of the CLEC5A pathway was associated with a significant increase in the clinical severity, including bone destruction (Joyce-Shaikh et al. 2010). The therapeutic potential of this pathway was demonstrated by improvement in the clinical course by intravenous administration of a CLEC5A-Fc fusion protein. The Fc binding site was mutated to attenuate antibody binding, and the fusion protein presumably bound to and blocked an unknown ligand for CLEC5A. Similar results were achieved by deleting the CLEC5A gene in mice (Joyce-Shaikh et al. 2010). The PBMC of patients with active rheumatoid arthritis expressed higher levels of CLEC5A (surface expression and mRNA) and exhibited greater incremental increases in CLEC5A expression in response to TNF-α or IL-1β. Expression levels on monocytes and PBMCs were positively correlated with markers of rheumatoid arthritis severity and inflammatory cytokines (Chen et al. 2014).

Chronic obstructive pulmonary disease is largely caused by cigarette smoking. A role for CLEC5A in COPD progression was suggested by a significant increase in CLEC5A expressing macrophages from smokers and abrogated inflammatory responses in a mouse model of COPD with CLEC5A-deficient mice (Wortham et al. 2016). Coronary artery disease risk is associated with common haplotypes at the 9p21.3 locus (Consortium et al. 2013). Macrophages from patients with a previous myocardial infarction had 1.5 fold greater mRNA expression of CLEC5A in patients with the 9p21.3 risk haplotype (Zollbrecht et al. 2013). It was speculated that CLEC5A-mediated inflammatory responses may contribute to atherosclerosis. Finally, a study of kidney transplant biopsy specimens with borderline changes for rejection showed a greater risk of subsequent deteriorating renal function from patients with higher levels of CLEC5A mRNA in biopsy tissue (Hruba et al. 2015).

Summary

CLEC5A is a C-type lectin that activates macrophages and osteoclasts by signaling through DAP-12 and DAP-10. CLEC5A binds to Dengue and Japanese encephalitis virus, but specific viral ligands remain unknown. There are no known endogenous ligands. CLEC5A has a role in the pathogenesis of inflammatory arthritis in a mouse model and contributes to dengue virus and Japanese encephalitis virus-induced lethality. Future research objectives include characterization of endogenous and pathogen ligands, understanding the cell surface events that lead to signaling through DAP-12, assessing its role in other TNF-α-mediated diseases such as inflammatory bowel disease, and exploring the therapeutic potential of CLEC5A blockade.

References

  1. Aoki N, Kimura S, Xing Z. Role of DAP12 in innate and adaptive immune responses. Curr Pharm Des. 2003;9:7–10.CrossRefPubMedGoogle Scholar
  2. Aoki N, Kimura Y, Kimura S, Nagato T, Azumi M, Kobayashi H, et al. Expression and functional role of MDL-1 (CLEC5A) in mouse myeloid lineage cells. J Leukoc Biol. 2009;85:508–17. doi: 10.1189/jlb.0508329.CrossRefPubMedGoogle Scholar
  3. Aoki N, Zganiacz A, Margetts P, Xing Z. Differential regulation of DAP12 and molecules associated with DAP12 during host responses to mycobacterial infection. Infect Immun. 2004;72:2477–83.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL. Myeloid DAP12-associating lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA. 1999;96:9792–6.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Bakker AB, Hoek RM, Cerwenka A, Blom B, Lucian L, McNeil T, et al. DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming. Immunity. 2000;13:345–53. doi: 10.1016/S1074-7613(00)00034-0.CrossRefPubMedGoogle Scholar
  6. Batliner J, Mancarelli MM, Jenal M, Reddy VA, Fey MF, Torbett BE, et al. CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation. Mol Immunol. 2011;48:714–9. doi: 10.1016/j.molimm.2010.10.016.CrossRefPubMedGoogle Scholar
  7. Chen DY, Yao L, Chen YM, Lin CC, Huang KC, Chen ST, et al. A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients. PLoS One. 2014;9:e86105. doi: 10.1371/journal.pone.0086105.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY, et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature. 2008;453:672–6. doi: 10.1038/nature07013.CrossRefPubMedGoogle Scholar
  9. Chen ST, Liu RS, Wu MF, Lin YL, Chen SY, Tan DT, et al. CLEC5A regulates Japanese encephalitis virus-induced neuroinflammation and lethality. PLoS Pathog. 2012;8:e1002655. doi: 10.1371/journal.ppat.1002655.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Cheung R, Shen F, Phillips JH, McGeachy MJ, Cua DJ, Heyworth PG, et al. Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice. J Clin Invest. 2011;121:4446–61. doi: 10.1172/JCI57682.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Consortium CAD, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25–33. doi: 10.1038/ng.2480.Google Scholar
  12. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491:56–65. doi: 10.1038/nature11632.CrossRefGoogle Scholar
  13. Gingras MC, Lapillonne H, Margolin JF. TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol. 2002;38:817–24. doi:10.1016/S0161589002000044 [pii].CrossRefPubMedGoogle Scholar
  14. Gonzalez-Dominguez E, Samaniego R, Flores-Sevilla JL, Campos-Campos SF, Gomez-Campos G, Salas A, et al. CD163L1 and CLEC5A discriminate subsets of human resident and inflammatory macrophages in vivo. J Leukoc Biol. 2015;98:453–66. doi: 10.1189/jlb.3HI1114-531R.CrossRefPubMedGoogle Scholar
  15. Gupta N, Lomash V, Rao PV. Expression profile of Japanese encephalitis virus induced neuroinflammation and its implication in disease severity. J Clin Virol. 2010;49:4–10. doi: 10.1016/j.jcv.2010.06.009.CrossRefPubMedGoogle Scholar
  16. Hruba P, Brabcova I, Gueler F, Krejcik Z, Stranecky V, Svobodova E, et al. Molecular diagnostics identifies risks for graft dysfunction despite borderline histologic changes. Kidney Int. 2015;88:785–95. doi: 10.1038/ki.2015.211.CrossRefPubMedGoogle Scholar
  17. Huang YL, Chen ST, Liu RS, Chen YH, Lin CY, Huang CH, et al. CLEC5A is critical for dengue virus-induced osteoclast activation and bone homeostasis. J Mol Med (Berl). 2016; doi: 10.1007/s00109-016-1409-0.PubMedGoogle Scholar
  18. Inui M, Kikuchi Y, Aoki N, Endo S, Maeda T, Sugahara-Tobinai A, et al. Signal adaptor DAP10 associates with MDL-1 and triggers osteoclastogenesis in cooperation with DAP12. Proc Natl Acad Sci U S A. 2009;106:4816–21. doi: 10.1073/pnas.0900463106.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Joyce-Shaikh B, Bigler ME, Chao CC, Murphy EE, Blumenschein WM, Adamopoulos IE, et al. Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. J Exp Med. 2010;207:579–89. doi: 10.1084/jem.20090516.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Lanier LL. DAP10- and DAP12-associated receptors in innate immunity. Immunol Rev. 2009;227:150–60. doi: 10.1111/j.1600-065X.2008.00720.x.CrossRefPubMedPubMedCentralGoogle Scholar
  21. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495–502. doi: 10.1038/ni1581.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature. 1998;391:703–7. doi: 10.1038/35642.CrossRefPubMedGoogle Scholar
  23. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2007;35:D26–31. doi: 10.1093/nar/gkl993.CrossRefPubMedGoogle Scholar
  24. Shin HS, Sarin R, Dixit N, Wu J, Gershwin E, Bowman EP, et al. Crosstalk among IL-23 and DNAX activating protein of 12 kDa-dependent pathways promotes osteoclastogenesis. J Immunol. 2015;194:316–24. doi: 10.4049/jimmunol.1401013.CrossRefPubMedGoogle Scholar
  25. Tybulewicz VL. Vav-family proteins in T-cell signalling. Curr Opin Immunol. 2005;17:267–74. doi: 10.1016/j.coi.2005.04.003.CrossRefPubMedGoogle Scholar
  26. UniProt C. UniProt: a hub for protein information. Nucleic Acids Res. 2015;43:D204–12. doi: 10.1093/nar/gku989.CrossRefGoogle Scholar
  27. Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol. 2006;7:524–32. doi: 10.1038/ni1325.CrossRefPubMedGoogle Scholar
  28. Watson AA, Lebedev AA, Hall BA, Fenton-May AE, Vagin AA, Dejnirattisai W, et al. Structural flexibility of the macrophage dengue virus receptor CLEC5A: implications for ligand binding and signaling. J Biol Chem. 2011;286:24208–18. doi: 10.1074/jbc.M111.226142.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Watson AA, O’Callaghan CA. Crystallization and X-ray diffraction analysis of human CLEC5A (MDL-1), a dengue virus receptor. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010;66:29–31. doi: 10.1107/S1744309109047915.CrossRefPubMedGoogle Scholar
  30. Wortham BW, Eppert BL, Flury JL, Garcia SM, Donica WR, Osterburg A, et al. Cutting Edge: CLEC5A Mediates Macrophage Function and Chronic Obstructive Pulmonary Disease Pathologies. J Immunol. 2016;196:3227–31. doi: 10.4049/jimmunol.1500978.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Wu MF, Chen ST, Yang AH, Lin WW, Lin YL, Chen NJ, et al. CLEC5A is critical for dengue virus-induced inflammasome activation in human macrophages. Blood. 2013;121:95–106. doi: 10.1182/blood-2012-05-430090.CrossRefPubMedGoogle Scholar
  32. Xavier-Carvalho C, Gibson G, Brasil P, Ferreira RX, de Souza SR, Goncalves Cruz O, et al. Single nucleotide polymorphisms in candidate genes and dengue severity in children: a case-control, functional and meta-analysis study. Infect Genet Evol. 2013;20:197–205. doi: 10.1016/j.meegid.2013.08.017.CrossRefPubMedGoogle Scholar
  33. Yang YL, Chang WP, Hsu YW, Chen WC, Yu HR, Liang CD, et al. Lack of association between CLEC5A gene single-nucleotide polymorphisms and Kawasaki disease in Taiwanese children. J Biomed Biotechnol. 2012;2012:398628. doi: 10.1155/2012/398628.PubMedGoogle Scholar
  34. Yim D, Jie HB, Sotiriadis J, Kim YS, Kim YB. Molecular cloning and expression pattern of porcine myeloid DAP12-associating lectin-1. Cell Immunol. 2001;209:42–8. doi: 10.1006/cimm.2001.1782.CrossRefPubMedGoogle Scholar
  35. Zeller T, Wild P, Szymczak S, Rotival M, Schillert A, Castagne R, et al. Genetics and beyond--the transcriptome of human monocytes and disease susceptibility. PLoS One. 2010;5:e10693. doi: 10.1371/journal.pone.0010693.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Zollbrecht C, Grassl M, Fenk S, Hocherl R, Hubauer U, Reinhard W, et al. Expression pattern in human macrophages dependent on 9p21.3 coronary artery disease risk locus. Atherosclerosis. 2013;227:244–9. doi: 10.1016/j.atherosclerosis.2012.12.030.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Michael E. Reschen
    • 1
  • Christopher A. O’Callaghan
    • 1
  1. 1.Centre for Cellular and Molecular Physiology, Nuffield Department of Clinical MedicineUniversity of OxfordHeadington, OxfordUK